<DOC>
	<DOCNO>NCT00003670</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth ovarian cancer cell . Hormone therapy use arzoxifene hydrochloride may fight ovarian peritoneal cancer block use estrogen tumor cell . PURPOSE : This phase II trial study well arzoxifene hydrochloride work treat woman metastatic refractory ovarian cancer primary peritoneal cancer .</brief_summary>
	<brief_title>Hormone Therapy With Arzoxifene Hydrochloride Treating Women With Metastatic Refractory Ovarian Cancer Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate response rate arzoxifene hydrochloride patient metastatic refractory ovarian epithelial cancer primary peritoneal cancer . II . Determine time progressive disease , time treatment failure , response duration , survival patient . III . Assess safety treatment patient . IV . Measure change serum estradiol , follicle stimulate hormone , luteinizing hormone , sex hormone bind globulin treatment patient . OUTLINE : Patients receive oral arzoxifene hydrochloride daily fix dose . Treatment continue absence unacceptable toxicity disease progression . PROJECTED ACCRUAL : Not specify National Cancer Institute ( NCI ) register trial Eli Lilly sponsor . NCI update record trial complete . In June 2012 , NCI transfer trial Lilly 's clinicaltrials.gov account Lilly update record trial completion date . This trial applicable trial Food Drug Administration Amendments Act 2007 ( FDAAA ) .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic refractory ovarian epithelial cancer OR primary peritoneal cancer provide clinical pathological feature tumor similar primary ovarian epithelial carcinoma Patients must receive prior chemotherapy include least one platinum analogue one taxane analogue unless patient poor candidate treatment due neuropathy , nephropathy , hypersensitivity ( Taxol ) Bidimensionally measurable disease xray , CT scan , MRI , physical exam Ascites consider measurable evaluable Hormone receptor status : Estrogen receptor status must know tissue must available analysis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Sex : Female Menopausal status : Not specify Life expectancy : At least 24 week Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL ( transfusionindependent ) Prothrombin time activate partial thromboplastin time great 1.25 time upper limit normal ( ULN ) Hepatic : Bilirubin great 1.5 time normal ALT AST great 2.5 time ULN ( ALT AST great 5 time ULN presence liver metastasis ) Renal : Creatinine great 1.5 ULN Other : No malignancy within past 5 year except adequately treat nonmelanomatous cancer skin carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No 2 prior chemotherapy regimen ( include repeat drug combination ) patient potentially platinumsensitive disease No 3 prior chemotherapy regimen ( include repeat drug combination ) patient platinum resistant disease At least 6 week since mitomycin nitrosoureas At least 3 week since prior chemotherapy Recovered prior chemotherapy Endocrine therapy : At least 3 week since hormone replacement therapy No prior hormonal therapy ovarian cancer Radiotherapy : At least 2 week since prior radiotherapy recover Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>